Evaluation of a multifaceted implementation strategy of three Clinical Practice Guidelines on cardiovascular risks in primary health care in the Basque Country

Evaluation of a multifaceted implementation strategy of three Clinical Practice Guidelines on cardiovascular risks in primary health care in the Basque Country: a cluster randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN88876909

Enrollment

780

Registered

2009-04-30

Start date

2009-01-01

Completion date

Unknown

Last updated

2018-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular risk, hypertension, diabetes, dyslipemia Circulatory System

Interventions

Control group (usual intervention): guidelines sent by post, electronic dissemination, presentations in health centres, limited number of workshops. Experimental group (multifaceted intervention): u

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary care units from two health districts (family physicians and nurses). Data will be taken from the computerised clinical records of all diabetics, hypertensive patients and general patients, who have attended the health centre over the last year for whatever reason.

Exclusion criteria

Exclusion criteria: Units, physicians and nurses who refuse to take part in the study

Design outcomes

Primary

Measure	Time frame
1. Hypertension: 1.1. Percentage of patients monitored over the study period (blood pressure and blood analysis registered) 2. Dyslipemia: 2.1. Percentage of patients (women >44 of age and men >39) whose coronary risk has been calculated during the study period 2.2. Percentage of patients with new statin prescription whose coronary risk was calculated during the previous year 3. Diabetes: 3.1. Percentage of patients with HbA1c determination during the study period All primary and secondary outcome measures will be assessed at the end of the study period, i.e., 18 months after initiation of intervention.	—

Measure

Time frame

1. Hypertension: 1.1. Percentage of patients monitored over the study period (blood pressure and blood analysis registered) 2. Dyslipemia: 2.1. Percentage of patients (women >44 of age and men >39) whose coronary risk has been calculated during the study period 2.2. Percentage of patients with new statin prescription whose coronary risk was calculated during the previous year 3. Diabetes: 3.1. Percentage of patients with HbA1c determination during the study period All primary and secondary outcome measures will be assessed at the end of the study period, i.e., 18 months after initiation of intervention.

—

Secondary

Measure	Time frame
1. Hypertension: 1.1. Systolic blood pressure (SBP), diastolic blood pressure (DBP) 1.2. Percentage of patients with good blood pressure control (140/90 mmHg) being treated with only one drug 1.4. Percentage of patients treated with an angiotensin II receptor blocker (ARB-II) 2. Dyslipemia: 2.1. Patients with coronary heart disease treated with statins All primary and secondary outcome measures will be assessed at the end of the study period, i.e., 18 months after initiation of intervention.	—

Measure

Time frame

1. Hypertension: 1.1. Systolic blood pressure (SBP), diastolic blood pressure (DBP) 1.2. Percentage of patients with good blood pressure control (140/90 mmHg) being treated with only one drug 1.4. Percentage of patients treated with an angiotensin II receptor blocker (ARB-II) 2. Dyslipemia: 2.1. Patients with coronary heart disease treated with statins All primary and secondary outcome measures will be assessed at the end of the study period, i.e., 18 months after initiation of intervention.

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 10, 2026